Evotec partner Celmatix, a biotechnology company focused on ovarian biology, today announced that a third milestone has been achieved in its five-year, multi-target alliance with Evotec. The milestone was triggered by Evotec and Bayer AG advancing a drug programme, centered around a novel Celmatix-identified drug target, into hit-identification.